A detailed history of Charles Schwab Investment Management Inc transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 403,361 shares of XERS stock, worth $1.38 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
403,361
Previous 404,582 0.3%
Holding current value
$1.38 Million
Previous $910,000 26.26%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$2.06 - $2.96 $2,515 - $3,614
-1,221 Reduced 0.3%
403,361 $1.15 Million
Q2 2024

Aug 12, 2024

BUY
$1.7 - $2.45 $65,091 - $93,808
38,289 Added 10.45%
404,582 $910,000
Q1 2024

May 08, 2024

BUY
$2.04 - $3.22 $3,898 - $6,153
1,911 Added 0.52%
366,293 $809,000
Q4 2023

Feb 06, 2024

SELL
$1.47 - $2.36 $927 - $1,489
-631 Reduced 0.17%
364,382 $856,000
Q2 2023

Aug 09, 2023

SELL
$1.82 - $2.98 $18,159 - $29,734
-9,978 Reduced 2.66%
365,013 $956,000
Q1 2023

May 11, 2023

BUY
$1.03 - $1.63 $27,556 - $43,609
26,754 Added 7.68%
374,991 $611,000
Q4 2022

Feb 13, 2023

BUY
$1.14 - $1.65 $11,867 - $17,176
10,410 Added 3.08%
348,237 $463,000
Q3 2022

Nov 14, 2022

SELL
$1.37 - $1.93 $771 - $1,086
-563 Reduced 0.17%
337,827 $528,000
Q2 2022

Aug 15, 2022

BUY
$1.48 - $2.64 $430,566 - $768,036
290,923 Added 612.9%
338,390 $522,000
Q1 2022

May 13, 2022

SELL
$2.0 - $2.87 $39,086 - $56,088
-19,543 Reduced 29.16%
47,467 $122,000
Q4 2021

Feb 11, 2022

BUY
$1.8 - $2.93 $120,618 - $196,339
67,010 New
67,010 $197,000

Others Institutions Holding XERS

About Xeris Biopharma Holdings, Inc.


  • Ticker XERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,956,992
  • Market Cap $466M
  • Description
  • Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...
More about XERS
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.